Cetera Investment Advisers’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-19,081
Closed -$580K – 2234
2022
Q4
$580K Buy
+19,081
New +$574K 0.01% 1297
2022
Q1
– Sell
-8,744
Closed -$369K – 1986
2021
Q4
$369K Sell
8,744
-4,199
-32% -$187K 0.01% 1373
2021
Q3
$589K Buy
+12,943
New +$594K 0.01% 1043
2021
Q2
– Sell
-8,439
Closed -$424K – 1821
2021
Q1
$424K Buy
8,439
+785
+10% +$43.5K 0.01% 1072
2020
Q4
$392K Buy
+7,654
New +$364K 0.01% 1092

Other funds holding SBIO

Cetera Investment Advisers's SBIO Position: Q1 2023 in Review

Cetera Investment Advisers sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q1 2023, closing a stake of 19,081 shares — an estimated $580K sold.

Cetera Investment Advisers first reported a position in SBIO in Q4 2020 and held it in 5 quarters. The position peaked at $589K in Q3 2021. 40 funds tracked by Wall St. Rank hold SBIO as of Q1 2023.

  • Cetera Investment Advisers reported no remaining ALPS Medical Breakthroughs ETF position as of Q1 2023 after selling out during the quarter.
  • Cetera Investment Advisers sold 19,081 ALPS Medical Breakthroughs ETF shares in Q1 2023, an estimated $580K.
  • Cetera Investment Advisers first reported a position in ALPS Medical Breakthroughs ETF in Q4 2020 and held it in 5 quarters.
  • Cetera Investment Advisers's ALPS Medical Breakthroughs ETF position peaked at $589K in Q3 2021.
  • 40 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q1 2023.

Based on Cetera Investment Advisers's 13F filing for Q1 2023, filed 15 May 2023.